A Celexa & Lexapro Case Revived By The 1st Court of Appeals
A Celexa & Lexapro Case Revived By The 1st Court of Appeals
Introduction
On January 30, 2019, the First Circuit Court of Appeals in Boston revived a lawsuit filed against Allergan PLC's Forest Laboratories with claims that the company illegally promoted the effectiveness of their antidepressants for children. However, the case was not allowed to proceed as a class action.
The lawsuit was brought by several plaintiffs whose child used both Celexa and Lexapro as antidepressants. United States District Judge Nathaniel M. Gorton dissolved Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation in 2018. Lawsuits filed against Forest laboratories claim the antidepressants are prone to cause birth defects and can induce suicidal behavior. A majority of cases involving Celexa and Lexapro were either dismissed or ended in settlements as of September 2018.
Comments
Latest News
Walgreens Settles Federal Opioid Case for $300 Million
Categories: Opioids
Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.
The U.S. Department of Justice announced on Monday…
Study: Opioid Use in Pregnancy May Shrink Newborn Brains
Categories: Opioids
New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…
Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting
Categories: Opioids
The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…